U.S. market Closed. Opens in 22 hours 10 minutes

NBRV | Nabriva Therapeutics plc Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Revenue35.67M27.22M2.86M7.75M6.50MN/AN/A84.00KN/AN/A
Cost of Revenue28.58M13.15M766.00K70.00KN/AN/AN/AN/AN/AN/A
Gross Profit7.09M14.07M2.10M7.68M6.50MN/AN/A84.00KN/AN/A
Operating Expenses58.26M62.60M68.22M87.17M120.88M73.77M55.05M26.84M9.89M6.74M
Selling, General & Admin45.26M51.65M55.28M62.48M41.74M29.47M13.44M7.82M3.46M3.91M
Research & Development14.26M12.63M15.10M26.41M82.29M49.62M47.99M22.73M8.59M10.11M
Other Operating Expenses-1.27M-1.68M-2.16M-1.73M-272.00K492.00K55.00K2.86M77.82K34.30M
Operating Income-51.17M-48.53M-66.13M-79.49M-114.38M-73.77M-55.05M-23.98M-9.77M22.31M
Other Expenses / Income-4.44M-432.00K-3.22M-3.17M-356.00K767.00K-515.00K2.86M-6.42M-5.76M
Before Tax Income-55.62M-48.96M-69.34M-82.66M-114.73M-73.00M-55.56M-31.82M-16.18M16.55M
Income Tax Expenses1.57M490.00K139.00K101.00K49.00K1.35M-672.00K-438.41K87.55K1.07M
Net Income-57.19M-49.45M-69.48M-82.76M-114.78M-74.36M-54.89M-31.39M-16.27M15.48M
Interest Expenses698.00KN/A1.74M3.64M133.00K43.00K75.00K14.59M6.98M5.55M
Basic Shares Outstanding2.68M1.73M513.80K296.80K203.18K119.32K85.91K42.34K108.82K108.82K
Diluted Shares Outstanding2.68M1.73M513.80K296.80K203.18K119.32K85.91K42.34K108.82K108.82K
EBITDA-54.70M-48.53M-64.85M-79.02M-114.09M-72.53M-54.42M-17.24M-9.75M28.06M
EBITDA Margin-153.36%-178.31%-2,264.42%-1,019.86%-1,755.20%0.00%0.00%-20,518.94%0.00%0.00%
EBIT-54.92M-48.96M-67.61M-79.02M-114.60M-72.96M-55.49M-17.24M-9.20M22.10M
EBIT Margin-153.97%-179.89%-2,360.68%-1,019.86%-1,763.05%0.00%0.00%-20,518.94%0.00%0.00%
Financial Year End2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙